A new role for vitamin D receptor activation in chronic kidney disease

2009 ◽  
Vol 297 (6) ◽  
pp. F1502-F1509 ◽  
Author(s):  
José M. Valdivielso ◽  
Jorge Cannata-Andía ◽  
Blai Coll ◽  
Elvira Fernández
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Mineral Metabolism ◽  
Receptor Activation ◽  
Left Ventricular ◽  
Traditional Use ◽  
Transplant Patients ◽  
Therapeutic Uses

Vitamin D has proven to be much more than a simple “calcium hormone.” The fact that the vitamin D receptor has been found in cells not related to mineral metabolism supports that statement. The interest of nephrologists in vitamin D and its effects beyond mineral metabolism has increased over the last few years, evidencing the importance of this so-called “sunshine hormone.” In the present review, we highlight the most recent developments in the traditional use of vitamin D in chronic kidney disease (CKD) patients, namely, the control of secondary hyperparathyroidism (sHPT). Furthermore, we also explore the data available regarding the new possible therapeutic uses of vitamin D for the treatment of other complications present in CKD patients, such as vascular calcification, left ventricular hypertrophy, or proteinuria. Finally, some still scarce but very promising data regarding a possible role of vitamin D in kidney transplant patients also are reviewed. The available data point to a potential beneficial effect of vitamin D in CKD patients beyond the control of mineral metabolism.

Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial

2018 ◽  
Vol 34 (5) ◽  
pp. 819-824 ◽  
Author(s):  
Graziella D’arrigo ◽  
Patrizia Pizzini ◽  
Sebastiano Cutrupi ◽  
Rocco Tripepi ◽  
Giovanni Tripepi ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Randomized Trial ◽  
Vitamin D Receptor ◽  
Receptor Activation ◽  
Double Blind ◽  
Soluble Thrombomodulin

Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease

2011 ◽  
Vol 33 (2) ◽  
pp. 139-149 ◽  
Author(s):  
Ravi Thadhani ◽  
Evan Appelbaum ◽  
Yuchiao Chang ◽  
Yili Pritchett ◽  
Ishir Bhan ◽  
...  
Keyword(s):  
Vitamin D ◽  
Kidney Disease ◽  
Left Ventricular Hypertrophy ◽  
Vitamin D Receptor ◽  
Ventricular Hypertrophy ◽  
Receptor Activation ◽  
Left Ventricular

scholarly journals Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Luciana Gravellone ◽  
Maria Antonietta Rizzo ◽  
Valentina Martina ◽  
Nicoletta Mezzina ◽  
Anna Regalia ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Mineral Metabolism ◽  
Controlled Trial ◽  
Protective Role ◽  
Hemodialysis Patients ◽  
Vitamin D Metabolites ◽  
Beneficial Effects

Vitamin D deficiency appears to be an underestimated risk factor for cardiovascular disease in patients with chronic kidney disease. Evidence from both basic science and clinical studies supports the possible protective role of vitamin D beyond its effect on mineral metabolism. Toxicity of pharmacologic doses of active vitamin D metabolites, in particular calcitriol, is mainly due to the possibility of positive calcium and phosphorus balance. Therefore, vitamin D analogs have been developed, which suppress PTH secretion and synthesis with reduced calcemic and phosphatemic effects. Observational studies suggest that in hemodialysis patients the use of a vitamin D receptor (VDR) activator, such as calcitriol, doxercalciferol, paricalcitol, or alfacalcidol, is associated with a reduced mortality when compared with nonusers of any VDR activator. In this article the existing literature on the topic is reviewed, although a more robust answer to the question of whether or not VDR activators have beneficial effects in hemodialysis patients will hopefully come from a randomized controlled trial.

Beneficial Effects of Selective Vitamin D Receptor Activation by Paricalcitol in Chronic Kidney Disease

2014 ◽  
Vol 15 (7) ◽  
pp. 703-709 ◽  
Author(s):  
Javier Donate-Correa ◽  
Virginia Domínguez-Pimentel ◽  
Mercedes Muros-de-Fuentes ◽  
Carmen Mora-Fernández ◽  
Ernesto Martín-Nunez ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Receptor Activation ◽  
Beneficial Effects

scholarly journals Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease

2012 ◽  
Vol 31 (1) ◽  
pp. 12-25 ◽  
Author(s):  
Sirous Darabian ◽  
Manoch Rattanasompattikul ◽  
Parta Hatamizadeh ◽  
Suphamai Bunnapradist ◽  
Matthew J. Budoff ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Cardiorenal Syndrome ◽  
Receptor Activation

scholarly journals Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease

2018 ◽  
Vol 21 (2) ◽  
pp. 128-134
Author(s):  
Lilit V. Egshatyan ◽  
Natalya G. Mokrisheva
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Receptor ◽  
Receptor Activation ◽  
Mineral Density

Secondary hyperparathyroidism is an early complication of chronic kidney disease, with increasing severity as the glomerular filtration rate decreases and characterized by a progressive increase in parathyroid hormone and growth of the parathyroid glands. It is generally accepted that a deficiency in active form of vitamin D or calcitriol levels seems to play a relevant role in its development and progression of secondary hyperparathyroidism. A reduction in plasma calcitriol levels occurs early in renal disease. Major renal guidelines recommend use of vitamin D for secondary hyperparathyroidism in chronic kidney disease. In the treatment vitamin D receptor activation inhibit glandular hyperplasia; reduce parathyroid hormone levels impact on bone turnover and mineral density. Treatment with calcitriol can occasionally result in hypercalcemia and hyperphosphatemia in renal patients due promotes intestinal calcium and phosphorus absorption. This limits its suitability for the treatment. But next generation vitamin-D analogs such as paricalcitol have lower intestinal absorption of calcium, phosphorous and significantly lowers renin levels, albuminuria and blood pressure. In this article, we present the case of a Caucasian male with type 2 diabetes and secondary hyperparathyroidism in stages 34 chronic kidney disease. Our case study shows that in treating for secondary hyperparathyroidisms selective vitamin D receptor activation with paricalcitol reduction of levels parathyroid hormone, albuminuria, offering low chance hypercalcemia, hyperphosphatemia and other side effects.

Sign in / Sign up

Export Citation Format

Share Document